This perspective discusses improved care options for midlife women through FDA label changes and personalized therapy.
This Perspective discusses the implications of the recent US Food and Drug Administration (FDA) label change on menopausal hormone therapy for clinicians to better integrate hormone therapy options and personalized, shared decision-making to improve care for midlife women.
No takes yet. Share an insight, caveat, or question.
Bartz et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: